Synairgen (LON:SNG) Stock Crosses Below 200 Day Moving Average of $14.55
Synairgen (LON:SNG) Stock Crosses Below 200 Day Moving Average of $14.55
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.Synairgen plc (LON:SNG – Get Rating)'s share price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 14.55 ($0.18) and traded as low as GBX 12.02 ($0.15). Synairgen shares last traded at GBX 13.22 ($0.16), with a volume of 269,782 shares.
在週四的交易中，Synairgen plc（LON: SNG — 獲取評級）的股價跌破了兩百天移動平均線。該股的兩百天移動平均線爲GBX 14.55美元（0.18美元），交易價格低至GBX 12.02（0.15美元）。Synairgen股票最後一次交易價格爲GBX 13.22美元（0.16美元），成交量爲269,782股。
Synairgen Trading Down 5.4 %
Synairgen 交易量下跌5.4％
The company has a market capitalization of £25.17 million, a PE ratio of -52.08 and a beta of -2.29. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.35 and a quick ratio of 6.35. The firm's 50 day moving average is GBX 10.73 and its 200 day moving average is GBX 14.53.
該公司的市值爲2517萬英鎊，市盈率爲-52.08，beta值爲-2.29。該公司的債務與權益比率爲0.09，流動比率爲6.35，速動比率爲6.35。該公司的50天移動平均線爲GBX 10.73，其200天移動平均線爲GBX 14.53。
Synairgen Company Profile
Synairgen 公司簡介
(Get Rating)
（獲取評分）
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Synairgen plc 發現並開發了治療呼吸系統疾病的藥物。它開發了 SNG001，一種用於治療 COVID-19 的吸入性干擾素 β；用於治療普通感冒和流感引起的哮喘的吸入性β干擾素（ifn-β）；正在進行治療或預防慢性阻塞性肺疾病的 IFN-β；以及用於治療特發性肺纖維化 (IPF) 疾病的 LOXL2 抑制劑。
Featured Articles
精選文章
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation's Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
- MarketBeat 週迴顧 — 4 月 17 日 — 4 月 21 日
- 2 只工業實力股息股票正在融化
- 寶潔將創下新高
- AutoNation的計劃讓分析師待在身邊
- Netflix 增加回購：它能否在 2023 年完成逆轉？
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Synairgen 每日的新聞和收視率 -在下面輸入您的電子郵件地址，通過Marketbeat.com的免費每日電子郵件時事通訊接收Synairgen及相關公司最新新聞和分析師評級的簡明每日摘要。
